tert-butyl N-[4-[(E)-3-dimethylaminoprop-2-enoyl]-6-methoxypyridin-3-yl]carbamate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl N-[4-[(E)-3-dimethylaminoprop-2-enoyl]-6-methoxypyridin-3-yl]carbamate
• 英文别名: (E)-tert-butyl (4-(3-(dimethylamino)acryloyl)-6-methoxypyridin-3-yl)carbamate；tert-butyl (E)-(4-(3-(dimethylamino)acryloyl)-6-methoxypyridin-3-yl)carbamate；tert-butyl N-[4-[(E)-3-(dimethylamino)prop-2-enoyl]-6-methoxypyridin-3-yl]carbamate
• 化学式: C₁₆H₂₃N₃O₄
• 分子量: 321.376
• InChiKey: XRMZLFSMDRDDMJ-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[4-[(E)-3-dimethylaminoprop-2-enoyl]-6-methoxypyridin-3-yl]carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以99.2%的产率得到6-甲氧基-1H-1,7-萘啶-4-酮
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS OF USE
  [FR] COMPOSÉS ET PROCÉDÉS D'UTILISATION

  摘要：

  本公开涉及一般与化合物和药物组合物相关的内容，这些化合物和药物组合物适用作为蛋白激酶的调节剂，并且适用于治疗至少部分由蛋白激酶介导的疾病的方法。

  公开号：

  WO2021173591A1
• 作为产物：
  描述：

  5-氨基-2-甲氧基吡啶 在 2,2,6,6-四甲基哌啶 、 正丁基锂 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 甲苯 为溶剂， 反应 2.0h， 生成 tert-butyl N-[4-[(E)-3-dimethylaminoprop-2-enoyl]-6-methoxypyridin-3-yl]carbamate
  参考文献：
  名称：

  Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors

  摘要：

  Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway provides a promising new approach for cancer therapy. Through a rational design, a novel series of thienopyrimidine was discovered as highly potent and selective PI3K inhibitors. These thienopyrimidine derivatives were demonstrated to bear nanomolar PI3K alpha inhibitory potency with over 100-fold selectivity against mTOR kinase. The lead compounds 6g and 6k showed good developability profiles in cell-based proliferation and ADME assays. In this communication, their design, synthesis, structure activity relationship, selectivity, and some developability properties are described.

  DOI：

  10.1021/ml5005014

文献信息

• [EN] COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS ET PROCÉDÉS D'UTILISATION
  申请人：EXELIXIS INC

  公开号：WO2021173591A1

  公开（公告）日：2021-09-02

  The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.

  本公开涉及一般与化合物和药物组合物相关的内容，这些化合物和药物组合物适用作为蛋白激酶的调节剂，并且适用于治疗至少部分由蛋白激酶介导的疾病的方法。
• [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2013061077A1

  公开（公告）日：2013-05-02

  The invention relates to new naphthyridine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  这项发明涉及新的萘啉衍生物化合物，包括所述化合物的药物组合物，制备所述化合物的方法以及利用所述化合物治疗疾病，例如癌症。
• Strategic studies in the syntheses of novel 6,7-substituted quinolones and 7- or 6-substituted 1,6- and 1,7-naphthyridones
  作者：Rémy Morgentin、Georges Pasquet、Pascal Boutron、Frédéric Jung、Maryannick Lamorlette、Mickaël Maudet、Patrick Plé

  DOI：10.1016/j.tet.2008.01.055

  日期：2008.3

  This paper describes the different strategies devised and applied to overcome the selectivity issues in the syntheses of 6,7-disubstituted-1H-quinolin-4-one, 7-substituted-1H-1,6-naphthyridin-4-one and 6-substituted-1H-1,7-naphthyridin-4-one derivatives. They allowed us to improve the overall yields and the scating-up feasibility. Several examples illustrate these strategies with their advantages and drawbacks. (C) 2008 Elsevier Ltd. All rights reserved.
• NEW COMPOUNDS
  申请人：ASTEX THERAPEUTICS LIMITED

  公开号：US20150057293A1

  公开（公告）日：2015-02-26

  The invention relates to new naphthyridine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
• NAPHTHYRIDINE DERIVATIVE COMPOUNDS
  申请人：ASTEX THERAPEUTICS LIMITED

  公开号：US20160108034A1

  公开（公告）日：2016-04-21

  The invention relates to new naphthyridine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.